Investigator

Menelaos Tzafetas

ST4 · Hillingdon Hospitals NHS Foundation Trust, Obstetrics & Gynaecology

MTMenelaos Tzafetas
Papers(1)
The intelligent knife…
Collaborators(2)
David MacIntyreMaria Kyrgiou
Institutions(1)
Imperial College Lond…

Papers

The intelligent knife (iKnife) and its intraoperative diagnostic advantage for the treatment of cervical disease

Clearance of surgical margins in cervical cancer prevents the need for adjuvant chemoradiation and allows fertility preservation. In this study, we determined the capacity of the rapid evaporative ionization mass spectrometry (REIMS), also known as intelligent knife (iKnife), to discriminate between healthy, preinvasive, and invasive cervical tissue. Cervical tissue samples were collected from women with healthy, human papilloma virus (HPV) ± cervical intraepithelial neoplasia (CIN), or cervical cancer. A handheld diathermy device generated surgical aerosol, which was transferred into a mass spectrometer for subsequent chemical analysis. Combination of principal component and linear discriminant analysis and least absolute shrinkage and selection operator was employed to study the spectral differences between groups. Significance of discriminatory m/z features was tested using univariate statistics and tandem MS performed to elucidate the structure of the significant peaks allowing separation of the two classes. We analyzed 87 samples (normal = 16, HPV ± CIN = 50, cancer = 21 patients). The iKnife discriminated with 100% accuracy normal (100%) vs. HPV ± CIN (100%) vs. cancer (100%) when compared to histology as the gold standard. When comparing normal vs. cancer samples, the accuracy was 100% with a sensitivity of 100% (95% CI 83.9 to 100) and specificity 100% (79.4 to 100). Univariate analysis revealed significant MS peaks in the cancer-to-normal separation belonging to various classes of complex lipids. The iKnife discriminates healthy from premalignant and invasive cervical lesions with high accuracy and can improve oncological outcomes and fertility preservation of women treated surgically for cervical cancer. Larger in vivo research cohorts are required to validate these findings.

1Works
1Papers
2Collaborators

Positions

2019–

ST4

Hillingdon Hospitals NHS Foundation Trust · Obstetrics & Gynaecology

2016–

Clinical Research Fellow

Imperial College London · Surgery & Cancer

2018–

ST3

West Middlesex University Hospital · Obstetrics & Gynaecology

2016–

Clinical Fellow

Queen Charlotte's and Chelsea Hospital · Obstetrics & Gynaecology

2014–

Clinical Fellow

Hillingdon Hospitals NHS Foundation Trust · Obstetrics & Gynaecology

2013–

Clinical Fellow

Queen Charlotte's and Chelsea Hospital · Obstetrics & Gynaecology

2011–

Clinical Fellow

Hillingdon Hospitals NHS Foundation Trust · Obstetrics & Gynaecology

Education

2009

MD

University Of Thessaly · Medicine